Cargando…
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
The metastatic non-small cell lung cancer (NSCLC) still remains an untreatable disease, and the role played by chemotherapy has yet to be defined. The new immunotherapeutic strategies, such as interferon and IL-2, seem to be also less effective, since they generally determine only a stabilisation of...
Autores principales: | Lissoni, P., Tisi, E., Barni, S., Ardizzoia, A., Rovelli, F., Rescaldani, R., Ballabio, D., Benenti, C., Angeli, M., Tancini, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977913/ https://www.ncbi.nlm.nih.gov/pubmed/1322155 |
Ejemplares similares
-
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
por: Lissoni, P., et al.
Publicado: (1994) -
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
por: Lissoni, P., et al.
Publicado: (1993) -
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
por: Lissoni, P., et al.
Publicado: (1989) -
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
por: Lissoni, P., et al.
Publicado: (1996) -
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
por: Lissoni, P., et al.
Publicado: (1991)